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A BST R AC T   
 
Aim: The identification of cellular pathways in colorectal tumor biology is essential for early diagnosis, 
treatment, and post-treatment follow-up. Osteopontin is an extracellular matrix protein that has regulatory 
physiological functions and roles in apoptosis, proliferation, adhesion, invasion, and tumor metastasis. In this 
study, we aimed to determine the prognostic and predictive value of osteopontin in colon adenocarcinoma. 
Our study investigated whether osteopontin expression had any prognostic or predictive use in colon 
adenocarcinoma and also if there were any differences between adenocarcinoma and adenoma.  
Methods: Fifty of these colonic specimens were adenocarcinoma, 16 were adenomatous polyps, and 10 were 
nontumoral colonic tissue that served as a control group. We used a two-tiered evaluation system that examined 
both the staining intensity and the percentage of staining.  
Results: The staining scores of tumors with vascular invasion were significantly higher than those of tumors 
without vascular invasion. In addition, the tumoral tissues’ osteopontin staining scores were significantly 
higher than the score of polyps.  
Conclusion: If future studies support our results, we suggest that osteopontin may be an important biomarker 
for predicting or detecting vascular invasion in tumors and could be useful in tumor-adenomatous polyp 
differentiation. Therefore, osteopontin can provide helpful information in the diagnosis and prognosis of colon 
adenocarcinoma. 
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Introduction 
Colorectal carcinoma is the most common 
carcinoma of the gastrointestinal system and is 
also the leading cause of death from cancer in 
some countries [1]. Depending on the 
incidence, morbidity, and mortality rates, colon 
carcinoma has a very important place among all 
tumors. Cancer development is a complex 
process that involves combinations of various 
tumor and tumor stromal-derived growth 
factors and cytokines. As demonstrated in other 
types of cancer, the identification of cellular 
pathways in colorectal tumor biology creates 
new opportunities for early diagnosis and future 
treatments. For this reason, many studies are 
being carried out at the cellular and molecular 
levels, and molecular level findings in 
particular play an important role in the 
prognosis since they assist in predicting the 
clinical course, patient follow-up, and 
application of treatment procedures. Some 
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markers are also used to assess the metastatic 
potential of a tumor [1-7].  
Osteopontin was first isolated from bone tissue 
in 1979. It a structural protein of bone tissue and 
an extracellular matrix protein found in the 
phosphoglucoprotein structure; osteopontin is 
also detected in other tissues of the body [2]. 
This substance plays many roles in cell-matrix 
interactions, the modulation of cell functions, 
and carcinogenesis [3]. These cancers include 
(but are not limited to) malignant breast cancer, 
osteosarcoma, melanoma, ovarian cancer, 
endometrial cancer, cervical cancer, renal 
cancer, oral cancer, esophageal cancer, gastric 
cancer, colorectal cancer, pancreatic cancer, 
liver cancer, lung cancer, head and neck cancer, 
glioblastoma, skin cancer, thyroid cancer, and 
sarcoma [4-7].   
In this study, we researched whether there was 
a significant relationship between osteopontin 
expression and prognostic parameters such as 
age, sex, localization, differentiation grade, 
lymph node involvement, vascular invasion, 
and cancer stage in colon adenocarcinomas. We 
also investigated whether there was any 
difference between adenocarcinoma and 
adenoma, which is an accepted precursor lesion 
of adenocarcinoma, for osteopontin 
expression.  
 
Materials and Methods 
We performed a retrospective review of 50 
patients who underwent colon resection and 
were diagnosed with adenocarcinoma at our 
hospital and 16 patients with adenoma that were 
diagnosed by biopsy during colonoscopy. 
Ethics Committee approval was obtained as 
Decision Number 25/08. Ten nontumoral colon 
tissues were selected as the control group. 
Information and patient records were obtained 
from the hospital automation system. 
Hematoxylin and Eosin (H&E) stained slides of 
archival paraffin blocks were evaluated. The 
degrees of differentiation were grouped as 
follows: well-differentiated if a tumor 
contained more than 95% of the glandular 
structure, moderately differentiated if the tumor 
involved 5=-95% of the glandular structure, and 
poorly differentiated if it contained 5–50% the 
glandular structure [1]. The tumor stage was 
assessed using TNM (Tumor-Node- 
Metastasis) classification. The cases were 
divided into two groups according to age (<65 
or ≥65 years), lateralization (right or left 
according to embryological development), and 
positivity (positive or negative) concerning 
lymph node involvement and the presence of 
vascular invasion. For each case, slides were 
selected to show the highest grade of a tumor 
and also examples of nontumoral tissue. 
 
Immunohistochemical staining method 
Immunohistochemistry was performed on the 
deparaffinized tissue sections obtained from 
formalin-fixed and paraffin-embedded tissue 
blocks. We used an automated slide stainer 
(Leica Bond Max device and osteopontin rabbit 
polyclonal antibody (RB-9097-R7) (Thermo 
Scientific) at a 1:50 dilution. The device 
staining procedure requires boiling the tissue 
sections in a 10-mM citrate buffer at a pH of 6:0 
for 20 minutes, followed by cooling for 20 
minutes. 
 
Scoring of the staining method 
Stomach adenocarcinoma was used as a 
positive control, and cytoplasmic staining with 
osteopontin was confirmed when slight nuclear 
staining was observed in cells where the 
staining was intense. We evaluated cytoplasmic 
staining in tumor epithelial cells. No significant 
specific staining pattern was observed in 
stromal structures. To assess the percentage of 
staining, we used a two-tiered scoring system 
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that included a combination of the staining 
intensity and the Allred Scoring System [8]. We 
developed a grading scale as follows: 
 Staining intensity 
      Score of 0: None 
      Score of 1: Weak 
      Score of 2: Moderate 
      Score of 3: Strong  
 Percentage of staining 
       Score of 0: 0% 
       Score of 1: ≤5% 
       Score of 2: 6–10% 
       Score of 3: 11–33% 
       Score of 4: 34–66% 
       Score of 5: 67–100% 
The sum of these two scorings led to a final 
score:    
       0–1: Score of 0 
       2–3: Score of 1 (+) 
       4–6: Score of 2 (++) 
       7–8: Score of 3 (+++) 
 
Statistical analysis 
Our statistical analysis was performed using the 
Statistical Package for the Social Sciences 
software, version 20.0. Categorical variables 
were presented as frequencies and percentages. 
Descriptive statistics were shown as the mean + 
standard deviation (SD) for numerical cut-off 
variables, and categorical variables were the 
number of cases and percentages (%). 
Pearson’s Chi-Square, Fisher’s Chi-square, or 
likelihood ratio tests were used to evaluate the 
categorical variables. Results with a p <0.05 
were considered statistically significant. 
 
Results  
The research population consisted of 76 people, 
42 (55.3%) males and 34 (44.7%) females. The 
youngest patient was aged 40, the oldest was 80 
years old, and 53% of the entire population 
were among the geriatric group (65 years and 
over). Tumors were found in 65.8% (n = 50) of 
the population, polyps were noted in 21.1% (n 
= 16), and nontumoral tissues were present in 
13.2% (n =10; Table 1). 
There was low grade dysplasia in 56.3% (n = 9) 
of the polyps and high grade dysplasia in 43.8% 
(n=7). Of the tumors, 86% (n = 43) were 
moderately differentiated, 8% (n = 4) were 
poorly differentiated and 6% (n = 3) were well 
differentiate. In 54% (n = 27) of tumor cases. 
Lymph node metastasis was present, and 46% 
(n = 23) presented with vascular invasion. 
According to TNM classification, 64% (n = 32) 
of the cases had invasion into subserosa (T3), 
12% (n = 6) into muscularis propria (T2), 22% 
(n = 11) into serosa (T4), and 2% (n = 1) into 
both mucosa and submucosa (T1). Gauging the 
tumors by the AJCC 2017 TNM stage, 36% (n 
= 18) were stage IIIB, 34% (n = 17) were stage 
IIA, 12% (n = 6) reached stage IIIC, 10% (n = 
5) presented as stage I, 4% (n = 2) were stage 
IIB, 2% (n = 1) were stage IIIA and 2% (n = 1) 
were stage IVA (Table 1). 
In the geriatric age group, 51.4% (n = 18) had 
score 3 staining and 48.6% (n = 17) had score 2 
staining present. The under 65 age group had 
score 3 staining present in 74.2% (n = 23) and 
score 2 staining in 25.8% (n = 8; p = 0.059). 
Score 3 staining was also present in 81% (n = 
17) of right localized tumors but was found in 
only 65.5% (n = 19) of left localized tumor 
cases; these findings were not statistically 
significant (p = 0.341) (Table 2). 
A significant relationship could not be found in 
epidemiological data comparisons, but 
significant differences were found between 
diagnoses and tumor characteristics, 
specifically with the staining score (p <0.001). 
Accordingly, we found that the score 2 staining 
rate was higher in adenomatous polyps, and the 
score 3 staining rate was higher in tumors 
(Table 2). 
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Score 3 staining was observed in all poorly 
differentiated tumors, in 70.3% (n = 26) of 
moderately differentiated tumors and 66.7% (n 
= 2) of well-differentiated tumors. An increase 
in the ratio of Score 3 staining corresponding 
with decreasing tumor differentiation did not 
show statistical significance (p = 0.637) (Table 
2). Score 3 staining was significantly higher in 

































without it (95.7%/ 51.9%, p = 0.001). While the 
staining score was not statistically significant 
for tumors with and without lymph node 
metastases, those with lymph node metastases 
had higher scores than those without 
(74.1%/69.6%, p = 0.726). No significant 
difference was found between tumor stage and 
subgroups (p=0.801) or depth of invasion (p= 


















































Age  (Med±SD) 66.4±11.2 66.1±11.7 67.4±9.6 0(0)  
Unknown 0(0) 0(0) 0(0) 10(100)  
<65 31(47) 24(48) 7(43.8) 0(0) 
0.993 
    ≥65 35(53) 26(52) 9(56.3) 0(0) 
Gender      
Female 34(44.7) 25(50) 6(37.5) 3(30) 
0.404 
Male 42(55.3) 25(50) 10(62.5) 7(70) 
Diagnosis      
Nontumoral colon tissue 10(13.2) 0(0) 0(0) 10(100) 
      - Adenocarcinoma 50(65.8) 50(100) 0(0) 0(0) 
 Adenomatous polyps 16(21.1) 0(0) 16(100) 0(0) 
Staining intensity      
Score 0 10(13.2) 0(0) 0(0) 10(100) 
<0.001* 
Score1 17(22.4) 9(18) 8(50) 0(0) 
Score 2 32(42.1) 28(56) 4(25) 0(0) 
Score 3 17(22.4) 13(26) 4(25) 0(0) 
Percentage of staining      
Score 0 10(13.2) 0(0) 0(0) 10(100) 
<0.001* 
Score 3 5(6.6) 3(6) 2(12.5) 0(0) 
Score 4 16(21.1) 7(14) 9(56.3) 0(0) 
Score 5 45(59.2) 40(80) 5(31.3) 0(0) 
Final score      
Score 0 10(13.2) 0(0) 0(0) 10(100) 
<0.001* Score 2 25(32.9) 14(28.0) 11(68.8) 0(0) 
Score 3 41(53.9) 36(72.0) 5(31.2) 0(0) 
* The results were considered significant at the *P < 0.05 level. Med±SD: Median ±Standart Deviation 
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Table 2. Distribution of final scores according to demographic and clinical findings. 
Variables 
Final score 
p Score 0 





Age     
Under 65 0(0) 8(25.8) 23(74.2) 
0.059 
65 and over 0(0) 17(48.6) 18(51.4) 
Gender     
Female 3(8.8) 11(32.4) 20(58.8) 
0.649 
    Male 7(16.7) 14(33.3) 21(50) 
Diagnosis     
Normal colon tissue 10(100) 0(0) 0(0) 
<0.001* 
Adenocarcinoma 0(0) 12(27.3) 32(72.7) 
Mucinous Adenocarcinoma 0(0) 2(33.3) 4(66.7) 
Tubular Adenoma 0(0) 6(75) 2(25) 
Tubulovillous Adenoma 0(0) 2(50) 2(50) 
Villous Adenoma 0(0) 3(75) 1(25) 
Dysplasia degree in polyps 0(0)    
Low 0(0) 6(66.7) 3(33.3) 
0.838 
    High 0(0) 5(71.4) 2(28.6) 
Differentiation     
Well 0(0) 1(33.3) 2(66.7) 
0.637 Moderately 0(0) 13(30.2) 30(69.8) 
Poorly 0(0) 0(0) 4(100) 
Invasion depth     
T4 0(0) 1(9.1) 10(90.9) 
0.296 T3 0(0) 11(34.4) 21(65.6) 
T2-T1 0(0) 2(28.6) 5(71.4) 
Vascular invasion     
Negative 0(0) 13(48.1) 14(51.9) 
0.001* 
Positive 0(0) 1(4.3) 22(95.7) 
Lymph node metastasis     
Negative 0(0) 7(30.4) 16(69.6) 
0.726 
Positive 0(0) 7(25.9) 19(74.1) 
Stage     
    Ι-ΙΙ 0(0) 7(29.2) 17(70.8) 
0.860 
ΙΙΙ- ΙV 0(0) 7(26.92) 19(73.07) 
Stage subgroups     
Ι 0(0) 2(40) 3(60) 
0.963 
ΙΙa 0(0) 5(29.4) 12(70.6) 
ΙΙb 0(0) 0(0) 2(100) 
ΙΙΙa 0(0) 0(0) 1(100) 
ΙΙΙb 0(0) 6(33.3) 12(66.7) 
ΙΙΙc 0(0) 1(16.7) 5(83.3) 
ΙVa 0(0) 0(0) 1(100) 
Localization     
Left 0(0) 10(34.5) 19(65.5) 
0.341 
Right 0(0) 4(19) 17(81) 
* The results were considered significant at the P < 0.05 level 
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Osteopontin is a sialic acid-rich 
phosphoglycoprotein as well as an extracellular 
matrix protein that binds integrins at the 
structure [9]. Since its discovery, extensive 
research has been conducted on its differing 
roles, as it is considered to be more than a 



































functions; it has also been shown in various 
studies to function in apoptosis, proliferation, 
adhesion, invasion, and tumor metastasis 
[10,11]. Many studies have shown that 
osteopontin is highly expressed in various 
cancers (such as breast, lung, prostate 
carcinomas, osteosarcoma, glioblastomas, and 
melanomas), which is useful in different ways 
 
Figure 1. Osteopontin expression; Evaluation for staining intensity; magnifications at x 200 (left to 
right). a) Score 1 cytoplasmic staining at a villous adenoma. b) Score 1 cytoplasmic staining at a 
moderately differentiated adenocarcinoma. c) Score 2 cytoplasmic staining at a moderately 
differentiated adenocarcinoma. d) Score 2 cytoplasmic staining at a moderately differentiated 
adenocarcinoma. e) Score 3 cytoplasmic staining at an adenocarcinoma. f) Score 3 cytoplasmic 
staining at a moderately differentiated adenocarcinoma. 
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[6,7]. Similarly, there are many reports of 
increased osteopontin expression in the 
regulation of cancer invasion, intra-
extravasation, and colonization for distant 
tissues [12,13]. We attempted to obtain 
meaningful results about the above parameters 
that would provide useful clues during patient 
diagnosis and follow-up after surgical 
resection. 
This study found the score 3 staining ratio 
(72%) to be significantly higher in the 
malignant population than in the polyp group 
(31.2%). However, score 2 staining was higher 
in the polyp group (68.8%) than in the 
malignant group (28%). In tumoral cases, 
osteopontin staining intensity was significantly 
higher in the scoring system than with polyp 
cases (p= 0.001). While insignificant, 
differences were found according to 
differentiation grade, with scoring 3 staining 
patterns present in 66% of well-differentiated 
tumors rising to universal occurrence among 
poorly differentiated cases. 
Vascular invasion is an established adverse 
prognostic factor in colorectal and other 
carcinomas [14]. Wei et al. have identified the 
top 15 genes (especially OLR1, GPNMB, 
PRRX1, and BCAT1) that co‐upregulate with 
OPN in human colon cancers 
pecimens, promoting cancer migration and 
invasion in various types of cancer [15]. A 
study carried out with hepatocellular carcinoma 
specimens suggested that OPN overexpression 
independently correlates with vascular invasion 
and predicts poor survival in patients 
undergoing hepatectomy for hepatocellular 
carcinoma [16]. In our study, we found that 
score 3 stainings were higher (95.7%) in 
patients with vascular invasion than those 
without (51.9%; p= 0.001, confirming that 
hypothesis. In a study with 82 colorectal 
carcinoma patients, Likui et al. found a 
significant correlation between osteopontin 
mRNA expression and lymph nodes so that 
venous metastases [17]. We could not find a 
significant correlation related to lymph node 
metastasis, but this may be due to having an 
insufficient number of patients. We did find that 
OPN staining was not associated with age or 
gender (p= 0.059 and p= 0.649, respectively) 
in tumors, polyps, and normal tissues (Table 2). 
We also observed significant differences in 
staining percentage and intensity scores across 
various parameters of osteopontin expression. 
However, some of them probably did not reach 
statistically significant levels, which might also 
be due to the number of cases investigated. 
Although the number of polyps in the study 
group was low, there was a significant 
difference in staining compared to patients with 
tumors. To find out whether an intramucosal 
carcinoma focus is present or has been 
developing, the widespread and intense staining 
of osteopontin will provide a meaningful 
warning sign when evaluating an adenomatous 
polyp biopsy. 
Vascular invasion is a significant negative 
prognostic factor for all cancers and colon 
cancer in particular. Pathologists may be unable 
to observe vascular invasion because of 
vascular invasion not being present in 
examined sections. Therefore, intense staining 
of the osteopontin can be beneficial when 
detecting vascular invasion. 
Conclusions 
We suggest that osteopontin could be a 
beneficial biomarker in predicting vascular 
invasion. If supported by an adequate case 
series, it may also provide valuable information 
regarding invasive-precursor distinction. 
Hence, high staining score with osteopontin 
could provide useful information about 
predicting prognosis and determining the 
treatment method of colon cancer.  
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